Comparative bioavailability of fluoxetine after transdermal and oral administration to healthy cats

American Journal of Veterinary Research

Volumn 64, Issue 8, 2003, Pages 994-998

  Ciribassi, John ^a   Luescher, Andrew ^b   Pasloske, Kirby S ^c   Robertson Plouch, Carol ^c   Zimmerman, Alan ^c   Kaloostian Whittymore, Liane ^c  

^a Chicagoland Veterinary Behavior Consultants   (United States)

^b PURDUE UNIVERSITY   (United States)

^c ELANCO ANIMAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; FLUOXETINE; NORFLUOXETINE; PHOSPHATIDYLCHOLINE; POLOXAMER; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CAT; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; SINGLE DRUG DOSE; SYSTEMIC CIRCULATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CATS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; HALF-LIFE; SEROTONIN UPTAKE INHIBITORS;

ANIMALIA; FELIS CATUS;

EID: 0041620400     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2003.64.994     Document Type: Article

References (17)

1. Wong DT, Horng JS, Bymaster FP, et al. A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sci 1974;15:471-479.
2. Wong DT, Bymaster FP, Reid LR, et al. Norfluoxetine enantiomers as inhibitors of serotonin uptake in brain. Neuropsychopharmacology 1993;8:337-344.
3. Willimann H, Wade P, Luisi PL, et al. Lecithin organogel as matrix for transdermal transport of drugs. J Pharm Sci 1992; 81:871-874.
4. Landsberg G, Hunthausen W, Ackerman L. Drugs used in behavioural therapy. In: Handbook of behaviour problems of the dog and cat. Oxford, England: Butterworth-Heinemann, 1997;47-64.
5. Jarvinen A, Grawander M, Nykanen S, et al. Steady-state pharmacokinetics of oestradiol gel in post-menopausal women: effects of application area and washing. Br J Obstet Gynaecol 1997; 104(suppl 16):14-18.
6. Simpson BS, Simpson DM Behavioral pharmacotherapy Part I. Antipsychotics and antidepressants. Compend Contin Educ Pract Vet 1996;18:1067-1081, 1203-1212.
7. Simpson BS, Simpson DM. Behavioral pharmacotherapy Part II. Anxiolytics and mood stabilizers. Compend Contin Educ Pract Vet 1996;18:1203-1212.
8. Pryor PA, Hart BL, Cliff KD, et al. Effects of a selective serotonin reuptake inhibitor on urine spraying behavior in cats. J Am Vet Med Assoc 2001;219:1557-1561.
9. Riviere JE, Papich MG. Potential and problems of developing transdermal patches for veterinary applications. Adv Drug Deliv Rev 2001;50:175-203.
10. Hoffman SB, Yoder AR, Trepanier LA. Bioavailability of transdermal methimazole in a pluronic lecithin organogel (PLO) in healthy cats. J Vet Pharmacol Ther 2002;25:189-193.
11. Martinez MN. Noncompartmental methods of drug characterization: statistical moment theory. J Am Vet Med Assoc 1998;213:974-980.
12. Riviere JE, Spoo JW. Chapter 51. Dermatopharmacology: drugs acting locally on the skin. Section 12. Specialty areas of pharmacology. In: Adams R, ed. Veterinary pharmacology and therapeutics. Ames, Iowa: Iowa State University Press, 1995;1050-1090.
13. Walters KA, Brain KR, Green DM, et al. Comparison of the transdermal delivery of estradiol from two gel formulations. Maturitas 1998;29:189-195.
14. Kornafel KL, March CM. Estradiol gel in the treatment of menopausal symptoms: a placebo-controlled double-blind case study of efficacy and safety. South Med J 1992;85:270-273.
15. Koo Lee C, Kitagawa K, Uchida T, et al. Transdermal delivery of theophylline using an ethanol/panasate 800-ethylcellulose gel preparation. Biol Pharm Bull 1995;18:176-180.
16. Jarvinen A, Nykanen S, Paasiniemi L. Absorption and bioavailability of oestradiol from a get, a patch and a tablet. Maturitas 1999; 3:103-113.
17. Scott M, Letrent KJ, Hager KL, et al. Use of transdermal amitriptyline gel in a patient with chronic pain and depression. Pharmacotherapy 1999;19:236-239.